Sign in

SYRA on OTC

Syra Health Corp

Syra Health Corp is an American employment agencies services company based in Carmel.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Click Holdings Ltd., Baiya International Group Inc. or GEE Group Inc., or pick any stock.

  • TickerSYRA on OTC1
  • IndustryServices-Employment Agencies1
  • HeadquartersCarmel, Indiana1
  • Incorporated inDE2
  • Business address1119 Keystone Way N., #201, Carmel, In 460322
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Using agile implementation staffing methodologies we make it seamless and cost-efficient to expand our client’s clinical personnel.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

34.4%Gross margin4
-12.5%Operating margin4
-12.4%Net margin4
-9.5%Revenue growth, 20254
-42.7%Return on equity4
-$447.9KFree cash flow4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Population Health brought in 74% of the revenue Syra Health Corp broke down this way in fiscal 2025.

  1. Population Health$5.3M474%up 157% from 2024
  2. Healthcare Workforce$1.9M426%down 68% from 2024
Products and services by year
Products and services20242025
Population Health$2.1M$5.3M
Healthcare Workforce$5.9M$1.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue66¢$4.7M
  • Research and development1¢$67.8K
  • Selling, general and admin15¢$1.1M
  • Other costs19¢$1.4M

Out of $7.2M in revenue.4 The company lost money this year.

Financial statements

Revenue564$7.2M in 2025+29% since 2022
0$2.0M$4.0M$6.0M$8.0M2022: $5.6M$5.6M20222023: $5.5M$5.5M2023−2%2024: $8.0M$8.0M2024+45%2025: $7.2M$7.2M2025−9%
Gross profit564$2.5M in 2025+134% since 2022
0$1.0M$2.0M$3.0M2022: $1.1M$1.1M20222023: $1.4M$1.4M2023+33%2024: $1.7M$1.7M2024+17%2025: $2.5M$2.5M2025+51%
Operating income564-$904.3K in 2025−57% since 2022
-$4.0M-$3.0M-$2.0M-$1.0M02022: -$2.1M-$2.1M20222023: -$2.9M-$2.9M2023+38%2024: -$3.8M-$3.8M2024+30%2025: -$904.3K-$904.3K2025−76%
Net income564-$896.3K in 2025−58% since 2022
-$4.0M-$3.0M-$2.0M-$1.0M02022: -$2.1M-$2.1M20222023: -$2.9M-$2.9M2023+39%2024: -$3.8M-$3.8M2024+28%2025: -$896.3K-$896.3K2025−76%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Net revenues$7.2M$8.0M
Cost of services$4.7M$6.3M
Gross profit$2.5M$1.7M
Salaries and benefits$1.5M$2.7M
Professional services$737.7K$606.1K
Research and development expenses$67.8K$585.1K
Selling, general and administrative expenses$1.1M$1.4M
Depreciation$20.5K$62.7K
Total operating expenses$3.4M$5.4M
Operating loss-$904.3K-$3.8M
Interest income$21.3K$21.2K
Interest expense-$13.3K-$15.6K
Total other income (expense)$8.0K$5.6K
Net loss-$896.3K-$3.8M
Weighted average common shares outstanding - basic11.9M shares7.6M shares
Weighted average common shares outstanding - diluted11.9M shares7.6M shares
Net loss per common share - basic-$0.08-$0.50
Net loss per common share - diluted-$0.08-$0.50

Compare Syra Health Corp with another company

Corporate structure

Syra Health Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Syra Health Corp

  • Neil Lawrence Johnson Filed SCHEDULE 13D on Syra Health Corp, latest Jan 16, 2026
  • Mike Edward McAleer Filed SC 13G on Syra Health Corp, latest Feb 20, 2024 (2 filings since Oct 12, 2023)
  • SLS GROUP LLC Filed SC 13G/A on Syra Health Corp, latest Feb 13, 2024 (3 filings since Oct 6, 2023)
  • Syra Health Corp Carmel, Indiana

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Syra Health Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$147.0K4 Dec 31, 2025$126.6K4 Dec 31, 2024+16.2%
Property and equipment, net$7.0K4 Dec 31, 2025$27.3K4 Dec 31, 2024−74.5%
Operating-lease assets (leased space)$27.4K4 Dec 31, 2025$299.2K4 Dec 31, 2024−90.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.6M4 Dec 31, 2025$2.4M4 Dec 31, 2024−32.6%

Properties, in its own words

Our corporate headquarters are located at 1119 Keystone Way N. #201 Carmel, IN 46032 pursuant to a three-year lease which commenced on July 1, 2021 and was amended on May 1, 2022 and provides for a monthly rent of $10,711. The lease was further amended on June 26, 2024 and provides for a base monthly rent of $11,209 per month, over a three-year term of the lease, which commenced on July 1, 2024. The lease was further amended on July 1, 2025, and provides for a base monthly rent of $5,580 from September 1, 2025 through May 31, 2026. We believe this to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.

Item 2 of the 10-K filed Mar 12, 2026.3

Leadership

Who has led Syra Health Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Deepika Vuppalanchi2023

Chair

  1. Sandeep Allam2023

President

  1. Sandeep Allam2023

Chief financial officer

  1. Priya Prasad2023–now

Chief operating officer

  1. Priya Prasad2023–now
2025
Board members and other officers (7)

Timeline

  1. Aug 11, 20268-K Results of operations18
  2. Jul 23, 20268-K Shareholder vote19
  3. May 7, 20268-K Results of operations20
  4. Mar 12, 20268-K Results of operations21
  5. Dec 18, 20258-K Executive or director change; Other events22
  6. Nov 18, 20258-K Bylaws or fiscal year changed23
  7. Nov 14, 20258-K Shareholder vote24
  8. Nov 12, 20258-K Results of operations25
  9. Aug 15, 20258-K Executive or director change26
  10. Aug 12, 20258-K Results of operations27
  11. Jul 30, 20258-K Executive or director change28
  12. Jun 17, 20258-K Executive or director change29
  13. Sep 28, 2023New chief executive Deepika Vuppalanchi becomes CEO9

Calendar

Coming up

  1. Around Nov 15, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.

When it reported results

  1. Aug 11, 2026Reported quarterly or annual results18
  2. May 7, 2026Reported quarterly or annual results20
  3. Mar 12, 2026Reported quarterly or annual results21
  4. Nov 12, 2025Reported quarterly or annual results25
  5. Aug 12, 2025Reported quarterly or annual results27
  6. May 8, 2025Reported quarterly or annual results30
  7. Mar 11, 2025Reported quarterly or annual results31
  8. Oct 29, 2024Reported quarterly or annual results32

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

158 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 29 major events, 41 insider forms, 6 large holders, 3 private raises, 66 other. The latest 20:

  1. Oct 9, 2026EFFECT EDGAR
  2. Oct 1, 2026POS AM EDGAR
  3. Sep 29, 2026RW EDGAR
  4. Sep 28, 20264/A EDGAR
  5. Sep 28, 20264/A EDGAR
  6. Sep 28, 20264/A EDGAR
  7. Sep 14, 2026S-1 EDGAR
  8. Sep 2, 20264 EDGAR
  9. Aug 14, 20264 EDGAR
  10. Aug 13, 2026S-8 EDGAR
  11. Aug 11, 202610-Q EDGAR
  12. Aug 11, 20268-K EDGAR
  13. Jul 23, 20268-K EDGAR
  14. Jun 1, 2026DEFA14A EDGAR
  15. Jun 1, 2026ARS EDGAR
  16. Jun 1, 2026DEF 14A EDGAR
  17. May 7, 202610-Q EDGAR
  18. May 7, 20268-K EDGAR
  19. Apr 27, 202610-K/A EDGAR
  20. Mar 12, 202610-K EDGAR

The 158 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 27 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 12, 2024Prasad PriyaCOO and CFOBuy5,303$0.38$2.0KForm 4
Feb 8, 2024Prasad PriyaCOO and CFOSale500$7.50$3.8KForm 4
Dec 21, 2023Prasad PriyaCOO and CFOBuy1$1.18$1Form 4
Dec 14, 2023Syed Feroz10% ownerBuy175$1.42$248Form 4
Dec 14, 2023Allam SandeepPresident and ChairBuy294$1.31$385Form 4
Dec 13, 2023Syed Feroz10% ownerBuy200$1.36$272Form 4
Dec 13, 2023Allam SandeepPresident and ChairBuy647$1.40$906Form 4
Dec 12, 2023Allam SandeepPresident and ChairBuy425$1.40$595Form 4
Dec 11, 2023Allam SandeepPresident and ChairBuy362$1.37$496Form 4
Dec 8, 2023Prasad PriyaCOO and CFOBuy50$1.23$62Form 4
Dec 8, 2023Allam SandeepPresident and ChairBuy193$1.30$251Form 4
Dec 7, 2023Prasad PriyaCOO and CFOBuy10$1.22$12Form 4
Dec 7, 2023Allam SandeepPresident and ChairBuy206$1.27$262Form 4
Dec 6, 2023Prasad PriyaCOO and CFOBuy50$1.22$61Form 4
Dec 6, 2023Syed Feroz10% ownerBuy200$1.33$266Form 4
Dec 6, 2023Allam SandeepPresident and ChairBuy398$1.29$513Form 4
Dec 5, 2023Prasad PriyaCOO and CFOBuy10$1.21$12Form 4
Dec 5, 2023Prasad PriyaCOO and CFOSale2,000$1.31$2.6KForm 4
Dec 5, 2023Syed Feroz10% ownerBuy320$1.34$429Form 4
Dec 5, 2023Allam SandeepPresident and ChairBuy1,145$1.32$1.5KForm 4

All 31 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Neil Lawrence JohnsonSCHEDULE 13D, 1 filing Jan 16, 202633
  • Mike Edward McAleerSC 13G, 2 filings Oct 12, 2023 to Feb 20, 202434
  • SLS GROUP LLCSC 13G/A, 3 filings Oct 6, 2023 to Feb 13, 202435

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Priya Prasad,47$4$273.0K36
2025Deepika Vuppalanchi,$150.9K$156.6K36
2025Sandeep Allam,$62.6K$63.1K36
2024Former ChiefExecutive Officer$271.9K$282.8K36
2024Former President and Chairman$193.0K$200.7K36
2024Chief Operating OfficerChief Financial Officer$164.7K$171.3K36

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$2.8M 2022–2023
Money received by yearMoney received by year, 2022–2023: $2.8M in all. Private raises (Form D) $2.8M.$0$1M$2M$3M2022 · Private raises (Form D): $2.3M20222023 · Private raises (Form D): $500.0K2023
Figures by year
YearPrivate raises (Form D)Total
2023$500.0K$500.0K
2022$2.3M$2.3M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 10, 2023Raised $500,000 in a private offering of debt37 Form D: $3 million offered in all Form D
  2. Aug 2, 2022Raised $1.3 million in a private offering of equity38 Form D: 23 investors so far Form D
  3. May 6, 2022Raised $1 million in a private offering of equity39 Form D: 22 investors so far Form D

SEC filer profile

How Syra Health Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSyra Health Corp1
  • CIK0001922335
  • Employer ID (EIN)85-40279953
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)7361 Services-Employment Agencies1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address1119 Keystone Way N., #201, Carmel, IN 460321
  • Phone(317) 922-09221
  • Shares outstanding13,839,169 as of Aug 11, 20268
  • Public float$979.5K as of Jun 30, 20253
  • AuditorM&K CPAS, PLLC, The Woodlands, TX PCAOB ID 2738; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 13, 20221
  • Filings158 in all: 8-K (29), 4 (25), CORRESP (14), 3 (12), 10-Q (9), UPLOAD (9), S-1/A (5), EFFECT (4)1
    All 35 form types

    10-K (3), 4/A (3), ARS (3), D (3), DEF 14A (3), DEFA14A (3), DRSLTR (3), S-1 (3), SC 13G (3), 424B4 (2), DRS (2), DRS/A (2), FWP (2), S-8 (2), SC 13G/A (2), 10-K/A (1), 25 (1), 3/A (1), 8-A12B (1), CERT (1), POS AM (1), PRE 14A (1), RW (1), S-1MEF (1), S-3 (1), S-3/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 11, 2026
    Proxy statement (DEF 14A) Jun 1, 2026
    Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareSYRA

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Syra Health Corp names in Item 1A of its 10-K filed Mar 12, 2026: 49 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Need for Additional Capital
  • Although we have generated approximately $7.2 million and $8.0 million of revenues for the years ended December 31, 2025 and 2024, respectively, our future profitability is uncertain.
  • We will require substantial additional funding and if we are unable to raise capital on favorable terms when needed, we could be forced to curtail, delay or discontinue our business.
  • Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
  • Risks Related to Our Business and Industry
  • We face significant competition, which may harm our business, results of operations or financial condition.
  • If we are unable to retain our existing customers or attract new customers, our business, financial condition, or results of operations could suffer.
  • Our business strategy and future success depend on our ability to cross-sell our solutions.
  • If we are unable to successfully expand our sales force productivity, sales of our solutions and the growth of our business and financial performance could be harmed.
  • An economic downturn or volatility could have a material adverse impact on our business, results of operations or financial condition.
  • Our ability to generate revenue could suffer if we do not continue to update and improve our existing solutions and develop new ones.
  • Achieving market acceptance of new or updated solutions is necessary in order for them to become profitable and will likely require significant efforts and expenditures.
The other 39 risks
  • Our business would be adversely affected if we cannot obtain, process or distribute data we require to provide our solutions.
  • Poor service, system errors or failures of our solutions to conform to specifications could cause unforeseen liabilities or injury, harm our reputation and have a material adverse impact on our business, results of operations or financial condition.
  • Disruptions in service or damages to our data or systems failures, could have a material adverse impact on our business, results of operations or financial condition.
  • Breaches and failures of IT systems and the sensitive information we transmit, use and store, expose us to potential liability and reputational harm.
  • We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems in providing certain of our solutions to our customers, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with customers, adversely affecting our brand and our business.
  • Failure by our customers to obtain proper permissions or provide us with accurate and appropriate information may result in claims against us or may limit or prevent our use of information, which could harm our business. Additionally, privacy concerns relating to our business could damage our reputation and deter current and potential customers from using our solutions.
  • It is difficult to predict the sales cycle and implementation schedule for our products and services.
  • Our independent content providers may fail to perform adequately or comply with laws, regulations or contractual covenants.
  • We may be liable for use of content we provide.
  • Our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders.
  • As we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of talent solutions, the demands on our business and our operating risks may increase.
  • Consolidation in the healthcare industry could adversely impact our business, financial condition and operating results.
  • If we do not continue to recruit and retain sufficient quality healthcare professionals at reasonable costs, it could increase our operating costs and negatively affect our business and our profitability.
  • The ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts may affect the demand for our services that could negatively affect our business.
  • Our work with government clients exposes us to additional risks inherent in the government contracting environment.
  • We may be a party to legal, regulatory and other proceedings that could result in unexpected adverse outcomes.
  • We may be liable for the misdiagnoses, mistreatment, injury or other harm to patients resulting from the use of data that we provide to health care providers, and any resulting claims could negatively impact our operating results and result in a decline in our stock price.
  • Our success depends in part on our ability to identify, recruit and retain skilled management and technical personnel. If we fail to recruit and retain suitable candidates or if our relationship with our employees changes or deteriorates, there could be a material adverse impact on our business, results of operations or financial condition.
  • Our ability to utilize loss carry forwards may be limited.
  • Unanticipated changes in tax laws may affect future financial results.
  • Our use and development of artificial intelligence products may result in reputational harm and liability.
  • Risks Related to Intellectual Property
  • The protection of our intellectual property requires substantial resources and protections of our proprietary rights may not be adequate.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • We depend on a small number of large customers and the loss of one or more major customers could have a material adverse effect on our business, financial condition and results of operations.
  • Risks Related to Government Regulations
  • We are subject to federal and state healthcare industry regulation including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding government contracting.
  • Risks Related to Our Class A Common Stock
  • Our common stock is a “penny stock,” which may make it more difficult for investors to sell their shares of common stock due to suitability requirements.
  • Our common stock is currently traded on the OTC QB Market, which may have an unfavorable impact on our stock price and liquidity.
  • Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock, which could depress the price of our common stock.
  • Since our common stock is currently quoted on the OTC QB Markets our stockholders may face significant restrictions on the resale of our common stock due to state “blue sky” laws and the sale of common stock in this offering is subject to state “blue sky” laws.
  • The market price of our Class A common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our Class A common stock.
  • Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.
  • The dual-class structure of our common stock as contained in our Certificate of Incorporation has the effect of concentrating voting control with those stockholders who held our Class B common stock. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transactions requiring stockholder approval, and that may adversely affect the trading price of our Class A common stock.
  • We cannot predict the effect our dual-class structure may have on the market price of our Class A common stock.
  • Our principal stockholders will continue to have significant influence over the election of our board of directors and approval of any significant corporate actions, including any sale of the Company.
  • We could be subject to securities class action litigation.
  • Anti-takeover provisions contained in our Certificate of Incorporation and our Amended and Restated Bylaws (“Bylaws”), as well as provisions of Delaware law, could impair a takeover attempt.
  • Our Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.
  • General Risk Factors
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.
  • We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our Class A common stock less attractive to investors.

Legal proceedings

From time to time, we may become a party to various legal actions and complaints arising in the ordinary course of business. In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39